Outcomes of Apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
ConclusionsMulti-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.Clinical trial registrationClinicalTrials.gov (NCT00412984).
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Coumadin | Heart | Stroke | Warfarin